MESO — Mesoblast Limited

Is MESO overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of October 3, 2026

Mesoblast Limited (MESO) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Biotechnology) last closed at $14.08. The rating moved from Overbought to Oversold on September 25, 2026.

See all oversold Healthcare stocks →

AI analysis

Mesoblast Limited (MESO) is a clinical-stage biologics/cell-therapy company whose near-term valuation is driven by late-stage program outcomes, regulatory clarity, and access/pricing decisions. Financial health is likely dependent on external funding or partnership milestones; absent definitive positive clinical or commercial catalysts, share performance will remain sensitive to broader risk-off market conditions and drug-pricing policy headwinds.

Key factors

  • Clinical-stage pipeline with potential late-stage assets that could drive value if regulatory approvals or positive pivotal data are achieved
  • Sector-wide investor interest in select late-stage biologics and insider/specialist purchases supporting secondary liquidity and M&A optionality
  • High dependence on regulatory outcomes and reimbursement decisions for commercial viability and revenue realization
  • Capital intensity and existing cash-burn profile that creates near-term funding and dilution considerations
  • Macro risk-off market tone and healthcare IPO cooling which can suppress capital access and near-term share price performance
  • Exposure to pricing pressure from ongoing drug-pricing policy debates and Medicare negotiation dynamics
  • Partnerships or licensing deals (historically typical for companies of this type) could materially de-risk commercialization and provide non-dilutive funding

Risks

  • Clinical trial failure or disappointing pivotal/late-stage data which would materially reduce valuation
  • Insufficient cash runway leading to dilutive financings at unfavorable terms
  • Adverse regulatory decisions or extended review cycles delaying commercialization
  • Downward pressure on pricing and access from Medicare negotiation/IRA-style policies and payer reimbursement constraints
  • Manufacturing scale-up challenges for complex cell/biologic products impacting supply and margins
  • Competition from other biologics, cell therapies, or alternative modalities that could capture market share
  • Sector-wide risk-off episodes that reduce investor appetite for speculative biotech and compress secondary funding windows
  • Geopolitical or macro shocks that tighten credit and capital markets, impeding partnership or M&A execution

See today's live rating, score and targets

Members see the live hourly rating for MESO — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.